Fetal exposure to adriamycin and cyclophosphamide for breast cancer during pregnancy

• Autores: Octavio Ballesta López, Virginia Bosó Ribelles, Eva Romá Sánchez, Laura Palomar Abad, Ana Santaballa Bertrán, Javier García Pellicer, José Luis Poveda Andrés
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 22, Nº. 3, 2020, págs. 171-174
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In this current case report and review, we describe the case of a 35-year-old pregnant woman who was diagnosed with a triple-negative breast cancer with T2N1 stage in December 2017. Mastectomy was performed in February 2018 as a primary therapeutic approach and adjuvant chemotherapy was scheduled. In April 2018 (28+2) shestarted four cycles of chemotherapy with adriamycin and cyclophosphamide (AC) until 35+3 weeks of gestation. All controls were normal during the chemotherapy treatment. At 37+3 weeks, she delivered a normal male baby and no congenital malformation was detected. Due to the high risk of fatal events in the fetal development, this case adds to the present literature that underlines that anthracycline-based chemotherapy combination during pregnancy provides an adequate benefit/risk profile for pregnant and baby after the second trimester of gestation